论文部分内容阅读
目的 :观察伊贝沙坦和苯那普利对早期糖尿病肾病合并高血压患者血压及尿白蛋白排泄率 (UAER)的影响。方法 :将 34例患者随机分伊贝沙坦组 (1 50 mg/次 ,1次 /日 ,1 8例 )和苯那普利组(1 0 mg/次 ,1次 /日 ,1 6例 )。两组均治疗 6个月 ,并观察其治疗前后血压及 UAER的变化。结果 :两组血压及 UAER均明显降低 (P<0 .0 1 ) ,但两组比较差异无显著性 (P>0 .0 5)。两组治疗后 UAER下降幅度与收缩压、舒张压下降幅度之间比较无显著相关性 (P>0 .0 5)。结论 :伊贝沙坦和苯那普利均能有效降低血压 ,减少尿蛋白的排泄 ,保护肾脏
Objective: To observe the effects of irbesartan and benazepril on blood pressure and urinary albumin excretion rate (UAER) in patients with early diabetic nephropathy complicated with hypertension. Methods: Thirty-four patients were randomly divided into two groups: one group receiving Irbesartan (1 50 mg / time, one time / day, 18 patients) and benazepril (10 mg once daily, ). Both groups were treated for 6 months, and observed before and after treatment of blood pressure and UAER changes. Results: The blood pressure and UAER in both groups were significantly decreased (P <0.01), but there was no significant difference between the two groups (P> 0.05). There was no significant correlation between the decrease of UAER and the decrease of systolic pressure and diastolic pressure after treatment (P> 0.05). Conclusion: Both irbesartan and benazepril can effectively reduce blood pressure, reduce urinary protein excretion and protect kidney